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Magnetic resonance imaging, a noninvasive imaging modality in clinical medicine produces soft tissue
anatomical pictures in any desired plane that are exquisite representation of the spatial distribution of mobile
protons present in human/animal tissues. In vivo magnetic resonance spectroscopy, on the other hand, is a
useful technique for studying metabolic processes in biological systems. In the last decade, magnetic
resonance imaging and in vivo spectroscopy methods have become an established tool in many areas of
biomedical research for example, in understanding the physiology of several disease processes, tumor
metabolism, and drug discovery process. In fact, in vivo magnetic resonance spectroscopy can be used for
diagnosis of a
 
specific disease pattern with biochemical/metabolic signature (marker), assessment of tumor
response to different treatment regimens, drug concentrations in tissues, drug efficacy and metabolism. The
advantage of in vivo magnetic resonance is its versatility and comprehensive characterization of normal and
diseased tissues. In this article, a few examples of in vivo magnetic resonance methods and their utility in
clinical, experimental and biological research are presented.
Key Words: Magnetic resonance imaging, In vivo MR spectroscopy, Morphology, Applications, Clinical,
Experimental, Biological, Metabolism, Tumor,  Cancer, Functional MRI
Proc. Indian natn Sci Acad.  B69 No.4  pp  423-446 (2003)
*E-mail: jagan1954@hotmail.com;  Tel: (011) 2659 3253/26850533; Fax: (011) 2686 2663
Introduction
Nuclear magnetic resonance (NMR), since its
discovery in 1940s, has played an important role in
many areas of physics, chemistry, and material
science. Initially NMR was used for chemical
structure elucidation, but simultaneously, its
potential in biological research, especially
medicine, was recognized. Shown and Elsken in
1950 investigated the water content of potato and
maple wood. Singer (1959) measured blood flow in
the tails of mice. In 1973, high-resolution
phosphorus (31P) NMR studies of intact blood cells
were reported (Moon & Richards 1973). Later,
Hoult et al. (1974) reported  31P NMR of freshly
excised rat leg muscle. Burt et al. (1976) reported
similar observations for other muscle types.
Ackerman et al. (1980) reported noninvasive 31P
NMR study of skeletal muscle and brain
metabolism in small animals using a surface coil.
W ith the availability of larger magnets extension to
human 31P MR studies, followed later.
MR imaging developments are largely based
on the work of Damadian who reported that the
NMR relaxation time constants (T1 and T2) are
different for normal and malignant tissues and
could have diagnostic value (Damadian 1971). In
1973, Lauterbur produced the first NMR image of
an object and called it as ‘zeuim atography’, using
magnetic field gradients (Lauterbur 1973). Later,
MR images of human organs such as the finger
(Mansfield & Maudsley 1976), hand (Andrew et al.
1977) and wrist (Hinshaw et al. 1977) were
reported. By mid 1980’s, added by developments
in magnet technology, RF electronics and powerful
computers, the full potential of magnetic resonance
imaging (MRI) as a clinical tool was realized.
Today, MR is experiencing a rapid expansion and
has achieved an amazing level of success as an
important tool to study disease processes in
clinical and experimental research. This rapid
growth is due to its noninvasive nature, use of
no ionizing radiation and its ability to generate
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high-resolution images. Also, the technique of in
vivo NMR spectroscopy (MRS) can be used as a
unique means to probe the biochemistry of
living systems and to gain diagnostic information
(Danielsen & Ross 1999). This diagnostic
information is derived from MRI and MRS or a
combination of both the approaches. MRI produces
a spatial display of the distribution of nuclei and
provides a morphological picture (anatomical
information) similar to those of CT scanning but
with superior contrast resolution. In addition,
recent advances in MRI methodology offer
higher spatial resolution (100 µm or less),
enabling detailed morphological/ anatomical
information from small animals.
In vivo MRS of cells, organs and tissues
both, in humans and animals, is an extension of
high-resolution NMR used for molecular structure
determination, but applied to more complex
systems. For example, it can be used to observe
different metabolites present in a particular
region of tissues and organs. The determination
of the concentration and relative levels of these
metabolites provides information about normal
and abnormal tissues. This technique can also be
used to monitor the response of tumors to various
therapeutic modalities and to understand the
different metabolic processes (Stark & Bradley
1998, Jagannathan 2001). For these reasons, both
MRI and MRS are increasingly being used in
clinical, experimental, pharmaceutical and
biological research. It is this link between clinical
and pre-clinical applications that renders MR as
an attractive tool (Jagannathan 2001). Even
though MRI and MRS have evolved more or less
independently, in vivo localized MRS in humans
and other living systems are mainly guided
through MR images. Thus, the success of MRI
has led to considerable interest in MRS as a
noninvasive probe to monitor the metabolism of
living systems. In short, MRI produces the
spatial map of the proton (hydrogen-1H)
distribution present in tissues/organs using
magnetic field gradients that are strong
compared to the molecular interactions, while
MRS deals with molecular interactions in the
absence of magnetic field gradients.
This review covers the basic concepts of MRI
and in vivo MRS in qualitative terms without the
use of quantum physics. In fact, it is beyond the
scope of this article to present a comprehensive
review of the theory and the various applications
of MRI and MRS. The organization and content
of the review are arranged in such a fashion that
would enable both, the readers, who are novice
to MR, and the active researcher who wishes to
refer to the article as a reference material.
Theory
NMR can be defined as the magnetic interaction
between the nuclei of atoms and the radio
frequency (RF) field in the presence of an external
magnetic field (B0). The theory is based on the spin
(I) properties of nuclei. Spin is defined as an intrinsic
angular momentum of a nucleus that is responsible
for the magnetic moment.
 
Nuclei of some elements,
for example, proton (1H) and phosphorus (31P)
behave as magnetic dipoles and without any
external influence are randomly oriented in tissues.
However, in presence of strong magnetic field (B
o
),
such as the powerful magnet of the MRI scanner,
these magnetic dipoles lines up either parallel or
anti-parallel to the externally applied magnetic field
(figure 1). More spins lines up in parallel
orientation, due to its lower energy state. By
applying a radio frequency RF pulse, these nuclei
Figure 1 A-C. A, Orientation of individual spins in human
tissue sample in the absence of external magnetic field; B
o
In the presence of an external magnetic field (B
o
), the  spins
orient themselves along the magnetic field direction with
some parallel and some anti-parallel to the magnetic field.
Transition between the energy levels is possible by the
application of RF energy (equivalent to ∆E) applied at the
resonant frequency (ν0) of the proton nucleus.
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can be flipped from a parallel to an anti-parallel
state. After the pulse, the nuclei return to the parallel
state thereby emitting RF energy.  The frequency of
the energy depends upon the strength of the
magnetic field of the main magnet of  the scanner.
By manipulating the magnetic field strength
across the body, different tissues of the body can be
labeled with different radio frequencies. The
sum of these frequencies is detected, sent back to
the computer and analyzed to produce images.
For in-depth details of the physical principles of
MR, the reader may refer to standard text-
books referred above as well as other review
articles (Raghunathan & Jagannathan 1996,
Raghunathan 1998).
Since the human body contains approximately
70% water, most MR images are acquired using
proton nuclei present in the water molecule. Each
water molecule have two associated hydrogen
atoms covalently bonded to an oxygen atom, and
there are approximately 5 x 1027 hydrogen nuclei
in an adult human body.  Most clinical MR images
rely on the strong signal of mobile protons in the
body that arise primarily from water and fat. The
images are pictorial representation of the spatial
distribution of these mobile protons. The density
of mobile protons in the tissue affects the image
contrast, in addition to other factors discussed
later in this article.
Relaxation Times
Most MR images are either T1- or T2- weighted
(vide infra). T1 and T2 refer to magnetic resonance
time constants that are intrinsic to a particular
tissue. T1 is the spin-lattice (longitudinal) relaxa-
tion time. As nuclei returns to the lower energy
state, energy is lost by the nuclei due to its inter-
action with the surrounding environment or
lattice. This process is called as spin-lattice or T1
relaxation time. T2 denotes the spin-spin (transverse)
relaxation time. This refers to the loss of energy due
to interaction with other nuclei aligned with the
magnetic field. T2 relaxation is actually confounded
by T2* relaxation, which is much shorter and results
from inhomogeneity in the  main magnetic field.
While T1 and T2 relaxation times have been
separated for purposes of  discussion, it is important
to realize that they are occur simultaneously during
any given imaging procedure, and both contribute
to the imaging process. T1 and T2 are specific tissue
characteristics. Their value will vary depending on
factors such as magnetic field strength. Never-
theless, at a given field strength, different tissues
have different characteristic T1 and T2 (see table 1;
values from Stark & Bradley 1998) values.
Magnetic Field Strength and G radients
MRI systems are generally characterized by the
strength of the magnetic field. Most imaging
procedures are performed at field strengths in
the range of 0.2 to 1.5 Tesla, although imaging
outside this range is possible. The strength of the
magnetic field determines the resonance
frequency of water proton in the tissue.
Prior to the actual image acquisition process,
the magnetic field is homogeneous at all points
inside the magnet bore, for example, throughout a
patient’s body. However, during the data acquisi-
tion the gradient coils are switched on and off in a
pulsed fashion. The gradient coils are located within
the bore of the magnet, and when a current is
passed through the coils, the main magnetic field
(B
o
) changes linearly along the gradient. The
purpose of these gradient magnetic fields is two
fold- slice selection and pixel localization within the
slice. A combination of magnetic field gradient and
RF excitation at specific frequency permits slice
selection. The presence of a gradient field during
relaxation helps to localize the protons within the
slice that were selected during excitation.
Furthermore, steeper the gradient field, thinner
will be the slice. Similarly, narrow bandwidth RF
pulses, produce thinner slices. The gradient coils
consist of three pairs of each of the following: X, Y
and Z gradient. Mostly, Z gradient changes the
gradient magnetic field along the main magnetic
field (Z-axis) thereby allowing a slice selection for
imaging. X-gradient coils produce a magnetic field
Table 1 Relaxation times T1 and T2 at field strength of 1.5
Tesla for various tissues together with proton density (PD)
Tissue PD T1 T2
(%) (ms) (ms)
Brain gray matter 69 760 77
Brain white matter 61 510 67
Fat 90 260 80
Skeletal muscle 100 860 50
CSF 100 2650 280
Edema 86 900 77
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gradient across the patient (horizontal axis),
providing spatial localization along the X-axis of the
patient. This technique is usually called ‘frequency
encoding’. The Y-gradient coils produce antero-
posterior magnetic field gradient along patients,
and by convention, the Y-axis is used for ‘phase
encoding’ the NMR signal. Together, the Y- and
X-gradients precisely determine, where within the
imaging plane the NMR signal from each voxel or
pixel originates. The Z-gradient is always used for
selection of a transaxial plane and is called as ‘slice
selection gradient’. To select either of the axial,
sagittal or coronal planes for imaging, the Z-, X-, or
Y-gradients, respectively, will be energized as
magnetic fields add vectorially. When all the
three gradients are energized at the same time, an
oblique plane is defined.
Pulse Sequences
A pulse sequence is a set of instructions that
accomplishes two tasks. First, the sequence collects
the data in an orderly fashion to determine the
origin of the signal, i.e., the pixel position, which is a
function of the gradient magnetic fields outlined
earlier. Secondly, the sequence influences the image
contrast or pixel character by specifying the timing
and power of the RF pulses. Many of the
parameters that need to be specified in a pulse
sequence, such as the timing and magnitude of
gradient magnetic fields (normally denoted as G
x
or Gy or Gz) are included in the computer software.
A number of MRI pulse sequences are in use
and can be categorized into two main groups: (i)
the spin-echo (SE) and (ii) the gradient recalled
echo (GRE).  The images are acquired using
either a single-echo or a multi-echo approach
(Stark & Bradley 1998, Edelman et al. 1995). The
most commonly used sequences are spin echo,
partial saturation, inversion recovery, FLASH
(fast low angle shot), and GRASS (gradient
recalled acquisition in the steady state). The SE
pulse sequence shown in figure 2 is often used in
clinical diagnosis. The various timings and pulse
shapes of gradients are shown in figure 2.   In
order to get quality image with good contrast,
one needs to specify (a) type of pulse sequence,
(b) time intervals such as TR, TE,  (c) matrix size,
(d) number of signal averages, (e) plane of image,
(f) spatial separation of the slice, etc. Multi-slice
and multi-echo technique help to decrease total
Figure 2 Multi slice SE RF pulse sequence showing the various
time delays such as time of echo (TE), time of repetition (TR),
etc.  G
x
, Gy, and Gz refers to the gradient field applied along
X, Y and Z-axes. “Echo” refers to the NMR signal (FID).
scan time. Echo-planar imaging (EPI) (Mansfield
1977) which is widely used for image data
acquisition in very short time-scale, typically less
than 100 ms, is one of the approaches for rapid
scanning. EPI acquires a complete set of GREs
with a single shot or in a series of multiple shots.
EPI sequences are used in functional MRI, bolus
tracking, diffusion and perfusion studies (von
Schulthess 1997, Edelman et al. 1994).
Contrasts in MRI
The primary sources of inherent tissue contrast in
MRI are three-fold: proton density (PD), T1- and
T2-relaxation.  While PD
 
within soft tissue vary
by only a few percent, the proton contribution to
the measured MR signal tends to vary by a
greater amount, from a few percent up to 30%
among soft tissues.  Furthermore, T1 and T2
relaxation times often vary even more widely,
sometimes by more than 100% among soft tissues
(table 1), and it can have important effect on
image contrast (figure 3).  For example, the T1 of
cerebrospinal fluid (CSF) is many-fold higher than
white matter.  Similarly, inflated tissue (edema)
has higher T1 and T2 than normal white matter.
Few types of lesions, such as lipomas, melanomas,
and fibrous lesions deviate from this general rule
of having higher T1 and T2 values than the
surrounding normal tissues.  Although data on
proton density are limited, it often occurs that PD
values are directly correlated with relaxation
times. For example, normal tissues or lesions
having longer T1 and T2 values also tend to have
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higher PD values as has been demonstrated for
brain white matter lesions (Geis et al. 1989) and
appear to be generally true for most other lesions.
The pixel intensity in a MR image is a function of
T1, T2 and image acquisition parameters such as TR
and TE.  The effect of TE and TR on image contrast in a
typical SE imaging pulse sequence is given in table 2.
In routine MRI, the images obtained are either PD,
T1-weighted or T2-weighted images. They usually do
not refer to images that display pure PD, T1 or T2.
Instead, the terms refer to the relative weightage with
which these three parameters affect the tissue contrast
in MR images. Such images are obtained by varying
the TE and TR as given in table 2B. Generally, tissues
with short T1 will appear bright on T1-weighted
image, and tissues with long T1 will appear dark.
For example, in a T1- weighted image (from our
work on a volunteer) of a brain, the fat will
appear as white, white matter as light gray, gray
matter as dark gray, and CSF as black as shown
in figure 4A.  In a T2-weighted image of a brain
(figure 4B), fat appears as gray, white matter as
dark gray, gray matter appears as gray, and CSF
as white. In general, T1-weighted images are
useful for viewing anatomy (morphology)
while T2-weighted images are useful for
identifying the tissue pathology. MR images are
produced by assigning shades of gray, white, and
black to the strength of the signal produced by
the relaxing protons.
Applications of MRI
The advantage of MRI compared to the other
imaging modalities is the ability to image in any
orthogonal plane - axial, coronal, or sagittal as well as
in any desired oblique plane.  Owing to excellent soft
tissue contrast, even small structures, such as cranial
Figure 3  Relative MR signal intensities of tissues: (A) as a
function of the repetition time (TR) and (B) as a function
of the echo time (TE).
Table 2 A. Effect of TR and TE on image contrast in spin-echo
imaging
Table 2 B. A general rule to get PD, T1 and T2 weighted MR
images.
Figure 4 Transverse (axial) SE MR images of a volunteer: (A)
T1 - weighted [slice thickness = 5 mm; TR = 550 ms; TE = 15
ms; field of view (FOV) = 250 mm] and (B) T2- weighted (slice
thickness = 5 mm; TR = 2600 ms; TE = 90 ms; FOV = 250 mm).
Primary 
source
TE settings TR settings
T1 Short TE (< 25 ms) Comparable to T1s of 
the two tissues (towards 
shorter T1 is better) 
T2 Comparable to T2s 
of the two tissues 
(towards the 
longer T2 is better)
Long compared to the 
T1s of the two tissues 
(2000 ms or greater)
Proton 
Density 
(PD)
Short TE (< 25 ms) Long compared to the 
T1s of the two tissues 
(2000 ms or greater)
Long TE 
(> 70 ms) 
 T2 
Weighting 
Short TE 
(< 25 ms) 
T1 
Weighting  
PD
Weighting  
Short TR 
(300-700 ms) 
Long TR 
(2-3.5 s) 
A
B
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nerves, are clearly seen.  It is extremely useful
technique for diagnosing abnormalities in the central
nervous system  (CNS) and spinal cord (Stark &
Bradley 1998, Edelman  et al. 1995).  The T1- and T2-
relaxation times are long in most tumors and lesions
compared to the normal tissues. Thus tumors,
demyelinating diseases and other pathologies show
good contrast on T2-weighted images. It is a superb
method to study brain tumors because of excellent
soft tissue contrast resolution. Because of the absence
of artifacts due to bones, MRI is the method of
choice, for imaging vertex, posterior fossa, walls of
the middle fossa at the base of the skull, and orbits.
Smaller tumors are demonstrated better in MRI than
CT, usually without the need of contrast material.
MRI is also a good method for evaluating acoustic
neuromas, pituitary tumors, non-neoplastic disease,
ischemia, hemorrhage, arteriovenous mal-
formations, trauma, dis-orders of myelination,
dementia, infection, etc. The applications of MRI for
the study of spine are numerous, and the normal
anatomy of the spine (figure 5) is best defined in
sagittal plane (Monelfe 1992).
Cardiovascular MRI has emerged as a new
subspeciality, which provides anatomical and
functional assessment of the heart, evaluation of
myocardial viability, and coronary artery disease
(Duerinckx 1999, Van der Wall & de Ross 1991).
Cardiac MRI also offers direct visualization and
characterization of atherosclerotic plaques,
diseased vessel walls, and surrounding tissues
(Fayad & Fuster 2000). MRI can characterize
plaque and identify the presence of a thrombus or
calcification. Most cardiac imaging is obtained
using electro-cardiogram (ECG) or pulse
triggering to avoid image artifacts due to heart
motion. ECG triggering uses the electrical signal
of the heart to monitor the progression of the
heart motion. The R-wave is used as a reference
for starting MRI measurements and a freely
selectable delay time can be chosen to measure
various stages of the cardiac cycle. This method of
motion artifact suppression is useful to get rid off
any image blurring due to heart motion. Pulse
triggering works in a similar way. The pulse
pressure at the fingertip serves as synchronization
signal. Motion and flow artifacts are suppressed
with pulse triggering. This method is less complex
than ECG triggering and facilitates routine
examinations of the heart.  Recently, the cardiac
MR imaging is matured with the development of
new techniques to control motion and flow
artifacts. It is now possible to acquire quality
images of the heart using breath-hold technique.
Alternatively, three-dimensional navigator free-
breathing technique offers robust respiratory
motion compensation, good enough to visualize
coronary arteries (Hartnell et al. 1994, Wielopolski
et al. 1998). Moreover, with improvements in MR
hardware, such as fast gradients and high-
sensitivity radio-frequency coils, it is possible to
evaluate cardiac morphology, function, and
perfusion in a clinical setting. Also, its possible to
evaluate myocardial viability information, and
even coronary anatomy and flow. Due to excellent
soft tissue contrast, MRI also has wide application
in musculo-skeletal systems (Edelman et al. 1995,
Higgins et al. 1997).  MR image characteristics are
different for fat, muscle, fibrous structures, nerves
and blood vessels that are of considerable interest
to orthopedic surgeons and radiologists.
In the past few years, MRI of flow has evolved
into a powerful technique to visualize blood flow
in vessels. This technique called as magnetic
resonance angiography (MRA), which is proved to
be a valuable tool for evaluating vascular diseases
(Arlert et al. 1996).  In addition to its ability to
image vascular anatomy, new noninvasive
approaches for measuring blood flow have in fact
expanded the role of MRI in diagnosing vascular
Figure 5 T2 – weighted sagittal image (TR = 2800 ms; TE
= 90 ms, FOV = 400 mm) of the whole spine, showing
the different anatomy.
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pathology; for example, cardiac abnormalities and
renal blood flow (Van der Wall & de Ross 1991,
Arlert et al. 1996).  Moreover, it enables the
determination of flow velocity, direction, and even
the flow profiles within the vessel. The clinical
applications of MRA include the visualization of
arteriovenous malformations, aneurysms, venous
angiograms, carotid occlusion, thoracic vessels
and abdominal vessels. Figure 6 shows the MRA of
a patient carried out in our laboratory showing the
stenosis of both the left and right carotid arteries.
Recently, considerable interest has arisen in the
ability of MRI to image and measure molecular
diffusion and blood microcirculation (perfusion).
Diffusion and perfusion imaging (Le Bihan 1995,
Noris 2001) are useful techniques to evaluate
anatomic and functional disorders of the brain
and other organs. Both methods share some
conceptual points in common, however, refer
to different physical phenomena. Molecular
diffusion is the result of the thermal or
Brownian, random translational motion that
involves all molecules, while perfusion results
from blood delivery to tissuess.
Diffusion-weighted MR imaging  (DWMRI or
DWI) can be used to map as well as assess and/or
quantitate the microscopic motion of water protons
in tissues (Le Bihan 1995, Noris 2001). Measuring
molecular diffusion may bring several potentially
useful new approaches to tissue characterization
and functional studies. In tissue, interactions and
collisions of water molecule with macromolecules
and membranes usually limit diffusion, hence, in
biological studies the diffusion coefficient value is
quoted as apparent diffusion coefficient (ADC).
The local environment influences diffusion; for
example, in areas of white matter there is greater
diffusion along the myelin sheaths than across the
myelinated fiber.   Therefore, the diffusion of water
in tissues is anisotropic; i.e., there are different
apparent diffusion coefficients in each direction. In
fact, diffusion is a three-dimensional process and the
molecular mobility may not be the same in all
directions. This anisotropy may result from the
physical arrangement of the medium or from
asymmetric disposition of obstacles that limit
diffusion. In fact, diffusion is a tensor, an array of
numbers that describe mobility rates in different
directions. Diagonal elements D
xx
, Dyy, and Dzz
represent molecular mobility in the three directions
X, Y, and Z-axis. The non-diagonal elements, such
as D
xy, Dxz, or Dyz, show diffusion in one direction is
correlated with some molecular displacements in a
perpendicular direction. Since molecules can diffuse
in all three dimensions, diffusion tensor mapping
becomes more powerful. Diffusion imaging is a
major advancement in the continuing evolution of
MR imaging. It provides contrasts and characteri-
zation between tissues at cellular level that may
imply differences in function (Le Bihan 1995, Le
Bihan et al.2001).
DWI is useful in the early detection and
characterization of cerebral ischemia and is ideal
technique for stroke management (Le Bihan 1995,
Ozscunar & Sorensen 2000, Molko & Chabriat
2001). Figure 7 shows our data on diffusion-
weighted image of a patient who had stroke 12 hrs
prior to MRI. The infarct region is seen clearly as a
hyperintense area, which could not be clearly
differentiated in the T2-weighed image. Recently,
we have documented through sequential DWI
study, the occurrence of several pathological
features during the complete cycle of demyelination
and remyelination in an animal model of
demyelinating lesion (Degaonkar et al. 2002).
Perfusion MRI (PWI) measures blood flow,
which is different in many brain and cardiac
disorders (Le Bihan 1995, Barbier et al. 2001). In
fact, perfusion MR demonstrates the microscopic
vascular proliferation (neovascularization)
Figure 6 MR angiography (MRA) of a patient showing
stenosis (arrow) of carotid arteries.
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associated with tumor growth. Tissue perfusion is
normally assessed following a dynamic injection of
contrast material, gadolinium diethylene triamine
pentaacetic acid (Gd DTPA). For example, in
cerebral tissues Gd is restricted to the intra-
vascular space. Gd being paramagnetic creates
microscopic field gradients around the cerebral
microvasculature, resulting in a change of T2
relaxation and signal loss. From the amount of
signal loss, the concentration of gadolinium in each
pixel can be calculated, and a pixel by pixel relative
estimate of blood volume can be inferred. Maps of
cerebral blood volume (CBV) and CBF can be
generated using this information. As a rule, high-
grade tumors have higher CBV than low-grade
tumors; and CBV values correlate with the grade
of vascularity and mitotic activity. Knowledge of
tumor vasculature helps improve tumor grading,
identify optimal biopsy site in tumors with
heterogeneous vascularity, monitor malignant
degeneration and treatment efficacy, and
differentiate tumor recurrence from radiation
necrosis.  Similarly, PWI of the myocardium is a
useful modality to detect perfusion defects both, at
rest and under stress. Contrast enhanced (Gd
DTPA) PWI can be reliably used to assess
myocardial perfusion in patients with ischemia. The
uptake of contrast will be attenuated, in amplitude
and rate, in regions of compromised flow.
Yet another advance in MRI is to map changes
in brain hemodynamics that correspond to
different brain functions. The ability to observe
precise anatomical structures and its participation
in specific function is due to a technique called
‘functional MRI’ (fMRI).  fMRI provides high
resolution, noninvasive report of the neural activity
detected by a blood oxygen level dependent
(BOLD) signal (Ogawa et al. 1990, Merkle &
Ugurbil 1992, Ellerman & Ugurbil 1993).  It is
based on the increase in blood flow to the local
vasculature that accompanies neural activity in the
brain. This results in corresponding local
reduction in deoxyhemoglobin because, the
increase in blood flow occurs without an increase
of similar magnitude in oxygen extraction (De Yoe
et al. 1994). Since deoxyhemoglobin is paramag-
netic, it alters the T2* - weighted MR image signal
intensity. Thus deoxyhemoglobin is some times
referred to as an endogenous contrast-enhancing
agent, and serves as the source of the signal for
fMRI. Using an appropriate imaging pulse
sequence, human brain functions can be observed
without the use of exogenous contrast enhancing
agents in many clinical MR scanners (field 1. 5 T or
greater). Functional activity of the brain
determined from the MR signal has confirmed
anatomically
 
distinct processing areas in the visual
cortex (Fox & Raichle 1986, Belliveau et al. 1992),
the motor cortex (Kim et al. 1993, Jagannathan &
Raghunathan 1995), and Broca area of speech and
language related activities (Hinke  et al. 1993).
Figure  8  shows the effect of left-hand movement
performed by a volunteer (our work); the
appropriate cortical activity can be clearly seen
near the sulcal wall. The ability to directly observe
different brain functions opens an array of new
opportunities to advance our understanding of
brain organization, as well as a potential new
standard for assessing neurological studies and
risks (Moonen & Bandettin 2000, Buxton 2001).
MR imaging of nuclei other than proton, such as
23Na  and  19F, have also been reported.  Such
measurements are exacerbated by the low intrinsic
sensitivity of these nuclei relative to proton and the
low physiological concentrations relative to water.
Sodium MRI studies have demonstrated that the
method can be useful for monitoring edema
development, cerebral redistribution of sodium
Figure 7 Diffusion-weighted MRI of a patient imaged 12
hrs after stroke. The infarct region in seen as hyper-
intense area in the right occipital region.
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following ischemia (Lin et al. 2001) and myocardial
infarction (Sandstede et al. 2001). The technique has
also been found to be useful to detect early cartilage
degeneration (Shapiro et al. 2002). Since there is no
MR visible fluorine in human body, the 19F MRI
methodology depends on the exogenous addition
of a fluorinated material. Perfluorocarbons that
label vascular compartments at high concentration
have been commonly used, especially in the
assessment of vascularity and the kinetics of tissue
perfusion (McIntyre et al. 1999).
Recently, studies have shown that inhalation of
hyperpolarized (HP) gas allows images of the
human lung air spaces by MRI with excellent
contrast resolution (Albert et al. 1994, Ebert et al.
1996, Albert et al. 1999, Kauczor et al. 1998, Kauczor
2000, McAdams et al. 2000, Salerno et al. 2001).
Conventional proton MRI yields very poor images
of the lungs because they are filled with air and
contain little water.  Gases like 3He or 129Xe, both
chemically inert noble gases with spin 1/2, are
polarized by optical pumping before inhalation.
Nuclear polarization up to 80% is achieved which
corresponds to a huge polarization enhancement or
hyperpolarization above the thermal polarizations
obtained in standard MRI.  The method has immense
potential applications in the domain of lung
pathology and other perspectives in functional MRI.
MRI in Drug Evaluation
MRI is a useful technique in pharmaceutical and
drug research that enables us to understand the
pathophysiology of interaction of drugs with
tissue in vivo. This method allows evaluation of
the efficacy of drugs, including in vivo
concentration determination. In this section, few
specific examples of how MRI can be used in drug
evaluation are presented.
Cerebral infarction is the major cause of
mortality and morbidity in many countries. Despite
considerable research efforts, there is presently no
generally accepted therapy. MRI has been used to
investigate the early pathological events associated
with cerebral infarction in animal models, such as
unilateral occlusion of the common carotid artery in
gerbils (Buonano et al. 1983) or the middle cerebral
artery occlusion (MCAo) in animals (Sinha et al.
2001, Gupta et al. 2002). The MCAo model in rats
has also been used to test drugs with various
mechanisms, aimed at reducing the extent of
cellular damage in the acute phase of stroke. These
drugs are calcium antagonists, NMDA antagonists,
A M PA antagonists, ion channel modulators, anti-
inflammatory drugs, etc. In several cases, it was
demonstrated that the cytoprotective effects found
at 24 or 48h after MCAo persisted up to 14 and 28
days and could in these cases be considered
permanent (Sauter et al. 1988, Sauer et al. 1994).
Several drugs also showed efficacy when
administered after permanent MCAo (Sauter &
Rudin 1990).
DWI technique allows a more efficient and
accurate measurement of stroke volume in
experimental animal models. Recently Qui et al.
(Qui et al. 1997) have documented the progression
of a focal ischemic lesion in rat brain during
treatment with a novel glycine/NMDA antagonist
in vivo using 3D diffusion weighted MR study.
They have documented that the stroke volume
had increased by 15% in the control group, in
contrast, to the treated group that showed a 40%
reduced stroke volume.
Figure 8 Functional MR image of a volunteer who is
carrying out right hand finger movement. The appropriate
cortical activity in the left motor area (volunteers left)
 
is
shown as hyper intense signal on a T1-weighed MR image.
Note: the activation (white spots) that appear on right
side of the   image shown is actually the volunteer’s left.
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Of the several mechanisms of neuronal injury
in stroke, free radicals have also been implicated
during ischemia reperfusion. Melatonin, a potent
antioxidant, has been used in male Wistar rats
subjected to 2hr of transient MCAo to study its
effect on ischemia (Sinha et al. 2001).  Melatonin
(10,20 and 40 mg/kg i.p) was administered four
times to the animal at the time of MCAo, 1h after
MCAo, at the time of re-perfusion and 1h after re-
perfusion. In the 20 mg/kg melatonin tested
group, the percent ischemic volume in DWI was
significantly attenuated when compared to the
vehicle treated group. The study indicated that
melatonin has neuroprotective action in focal
ischemia, which may be attributed to its
antioxidant properties (Sinha et al. 2001). Similarly,
the effectiveness of adenosine as a neuroprotective
agent in MCA occluded rats using DWI has also
been demonstrated (Gupta et al. 2002).
Individual tumor physiology is one of the
important determinants in the outcome of non-
surgical treatments. Parameters such as tumor
blood flow, tissue oxygenation and nutrient
supply, pH distribution, and bioenergetic status
significantly influence tumor response to irradia-
tion, hyperthermia, chemotherapy and a combina-
tion of these modalities. In radiotherapy, the
efficacy of the treatment depends greatly on the
local oxygen concentration, which in turn, is
governed by local blood flow. Recently, calcium
channel blockers (CCB) have been observed to
modify the tumor blood flow in experimental
tumors (Wood & Hirst 1989). Diltiazem, belonging
to the benzothiazipine group of CCBs, has been
shown to protect normal tissues from the lethal
and sub-lethal effects of radiation. Recently,
Muruganandham et al. (1999) have used
gadodiamide contrast enhanced dynamic MRI to
investigate the diltiazem induced micro-
circulatory changes in tumor and normal muscle of
Swiss albino stain A mice. In addition, the MR
BOLD contrast method was also used to assess
tumor oxygenation status before and after
diltiazem administration. The diltiazem plus
radiation treated mice showed significant tumor
regression and enhanced animal survival. Thus,
this study revealed that diltiazem has the potential
as an adjuvant in radiation therapy apart from its
use in chemotherapeutic drug delivery
(Muruganandham et al. 1999).
In modern drug discovery and development,
transgenic and knockout animals are important as
disease models and for target validation. Several
examples of MRI and MRS applications in this field
have been reported (Koretsky et al. 1990, Roman
et al. 1996). The well-studied system is the creatine
kinase, which plays a critical role in the high-
energy phosphate (HEP) metabolism (Roman et al.
1996). In transgenic animals with increased
expression of creatine kinase in skeletal muscle, no
changes in the steady-state HEP levels have been
observed, despite increased contractile function.
In vivo  Magnetic Resonance Spectroscopy (MRS)
Although MRI is superior in giving information
about anatomy and pathology and is a proven
clinical diagnostic tool, MRI often lacks
biochemical specificity. Another application of
clinical MR is in vivo MR spectroscopy which is
capable of providing biochemical (metabolic)
information from a well-defined region of
interest of living systems, for example, the human
brain (Danielson & Ross 1999). In MRS the data
obtained is presented as spectra (see figure 9)
and are not represented as images. In, MRI water
protons are used to create images, but there are
other protons of biologically significant molecules
(biochemicals) distributed throughout the human
tissues that are not seen in MRI. A small
proportion of these molecules is present in
sufficient concentrations to produce a measurable
MR signal. Because each has a unique frequency
(RF) specific to the biochemical itself (called
‘chemical shift’), and entirely distinct from the
frequency of water protons, a spectrum of tissue
chemistry results from particular area of a human
organ under investigation. Thus, a MR spectrum
is a curve or a plot of the MR signal intensity as a
function of MR frequency measured in units of
parts per million (ppm) relative to the frequency
of a reference compound (see figure 9B vide
infra). Each peak in a spectrum derives from a
different biochemical present in the tissue and its
integrated signal intensity or area is proportional
to the concentration of that particular biochemical.
For example, a MR spectrum can be used to
discriminate healthy tissues from cancerous
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tissue. This gives MRS the ability to provide
insight into the biochemical changes underlying a
particular disease. Information that normally
requires biopsies (invasive) can now be acquired
by MRS non-invasively, in vivo. At present, MRS
is being used in many areas of cancer research,
such as intracranial tumors (Luan & Zhang 1998,
Castillo & Kwock 1999), head and neck cancers
(Danielsen & Ross 1999), breast cancers
(Jagannathan et al. 1998,   1999,  2001), and
prostate cancers (Kurhanewicz et al. 2000,
Swanson et al. 2001).
Metabolites that are Detected by MRS
MRS can be carried out using different nuclei such
as 1H, 31P, carbon (13C), lithium (7Li) and fluorine
(19F), etc. 31p MRS provides information about
energy status [phosphocreatine (PCr), inorganic
phosphate (Pi) and nucleotide phosphates (NTP)],
phospholipid metabolites [phosphomonoesters
(PME), phosphodiesters (PDE)], intracellular pH
and free cellular magnesium concentration.
Natural abundance or enriched 13C MRS provides
information about glycolysis, gluconeogensis,
amino acids and lipids. Water-suppressed 1H MRS
shows total choline (TCho), total creatine (TCr),
lipids (Lip), glutamate (Glu), glutamine (Gln),
inositols (Ins), lactate (Lac), and N-acetyl
aspartate (NAA). 7Li and 19F MRS can be used to
study pharmacokinetics.
Figures 10 and 11 depict the metabolic
pathways (Scriver et al. 1989, Murray 2000) which
have become more relevant since the advancement
of in vivo MRS. This is because, it is possible to
detect certain biochemicals that participate in
different metabolic pathways. For example, PCr,
NTPs, etc., involved in energy pathways and NAA,
TCr, TCho, etc., involved in neurochemical pathways
mainly through  31P and 1H MRS, respectively.
Figure 10 depicts the major pathways of energy
metabolism that occur in cells of the body. Fatty
acids and sugars (largely glucose) serve as fuels to
provide energy to the cells on oxidation. Glucose
after entering the cell, may be either
 
stored as
glycogen, or metabolized by glycolytic and
oxidative pathways. In the absence of oxygen,
glucose may be converted to lactic acid, generating
limited amounts of ATP. In the presence of oxygen,
the citric acid cycle (or tricarboxylic acid cycle, TCA)
metabolizes the metabolic products of glucose or
fatty acids within the mitochondria producing CO2.
ATP generated from oxidative phosphorylation is
exported to the cytosol where it is used for cellular
work and in turn is hydrolyzed. The energy
producing reactions of biosynthesis (not shown in
the figure), muscle contraction and ion transport are
driven by the breakdown (hydrolysis) of high-
Figure 9  (A) T1-weighted axial MR image (TR = 550 ms;
TE = 15 ms; slice thickness = 4 mm; FOV = 230 mm) of a
patient suffering from a brain tumor (cranio
pharyngioma) in the floor of the third ventricle.   (B)
Proton MR spectrum from an 8 ml voxel from the nor-
mal position (temporal region) of the brain of the pa-
tient (TR = 3000 ms; TE = 135 ms; NS = 256).  (C) Proton
spectrum of the same patient from an 8 ml voxel posi-
tioned in the tumor region (TR = 3000 ms; TE = 135 ms;
NS = 256).
Figure 10 The metabolic pathway showing the energy and
neurochemical pathways. The biochemicals (metabolites)
shown in bold are detectable by proton and phosphorus MRS.
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energy phosphate bonds of ATP. Hydrolysis of
ATP produces ADP and Pi. In the presence of
oxygen, ADP and Pi reenter the mitochondria and
are re-synthesized to form ATP. Alternatively, ADP
may be subsequently converted to AMP,
adenosine, inosine, and ultimately uric acid.
In muscle (skeletal and cardiac) and brain, the
enzyme creatine kinase is responsible for
generating the storage form of high-energy
phosphate, PCr. When sufficient oxygen and fuels
are available to facilitate ATP synthesis, abundant
amounts of PCr are produced. In time of energy
crisis, when hypoxia, ischemia, or cell damage
inhibits ATP synthesis, PCr serves to maintain
ATP levels so that cellular work can continue.
However, if PCr stores are depleted and ATP is
not synthesized, ATP concentration will fall to a
point at which muscular contraction and ion
transport can no longer occur.
Inhibition of the sodium pump causes loss of
cellular potassium and increase of cellular sodium,
resulting in edema and cell death. Therefore,
conditions that impair cell function or viability such
as anoxia, ischemia, or tissue damage produce the
following events: (a) impairment of ATP synthesis
resulting in a fall of PCr and rise of Pi; (b) ultimately,
depletion of ATP concentration; and (c) production
of lactic acid, resulting in rise of tissue lactate
concentration and fall of pH. Restoration of tissue
oxygenation leads to a reversal of these events:
lactate concentrations fall, and pH returns to
control. ATP and PCr concentrations rise while Pi
falls. The phosphorous metabolites that are shown
in bold in figures 10 and 11 are detectable in vivo. In
addition, figure 11 presents the additional
biochemical pathways observed specifically in
brain cells (Danielsen & Ross 1999). Their linkage
with other standard pathways is also shown to
give an overview of the whole metabolic activity
in brain. The metabolites that can be picked up by
1H MRS in such pathways are presented in bold.
31P MR Spectroscopy
In fact, 31P MRS has become the tool of choice to
investigate noninvasively energy metabolism in
human muscle (Cozzone & Bendahan 1994) and
in tumors (Negendank 1992). It is widely used as
a technique to measure pH in vivo . Studies on
human muscle revealed that in normal exercising
muscle, the concentration of ATP remains
constant while PCr falls and Pi increases (Argov
et al. 2000). Intense exercise produces severe
intracellular acidosis and changes in pH. During
the recovery period PCr gradually increases, Pi
and A D P decrease, and pH returns to its rest
level. 31P MRS is also used for diagnosis and
monitoring of many mitochondrial diseases. The
level of PCr/Pi at rest in muscles was lower in
mitochondrial myopathy (Arnold et al. 1985).
High intracellular pHs in association with the
loss of PCr at rest has also been reported in the
muscle of patients with muscular dystrophy
(Griffiths et al. 1985, Younkin et al. 1987, Kemp
et al. 1993). In vivo 31P MRS is a useful tool to
monitor metabolic changes in disease processes
that affect the brain. Reduction in PCr and PDE
with increased PME is reported in meningiomas
(Newman et al. 1982) and other brain tumors
(Hubesch et al. 1989, Heindel et al. 1998, Maintz
et al. 2002).  31P MRS has also been used to
monitor metabolic changes in brain tumors after
radiation and chemotherapy (Segebarth et al.
1989).
Proton MR Spectroscopy
The majority of MRS applications have been on the
human brain especially using a proton nucleus. It
plays a vital role in the assessment of clinical trials,
including the monitoring of new drug therapies.
The clinical utility of MRS rests on two important
properties. First, the nature and concentration of
tissue biochemicals is remarkably consistent, hence
a “normal” tissue (e.g. brain) spectrum is readily
recognized. Secondly, a particular biochemical is of
clinical relevance in healthy and/or diseased state.
Figure 11 The metabolic pathway observed specifically
in brain cells. The biochemicals shown as bold are
detectable by proton MRS.
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Accordingly, abnormal brain MR spectra are
readily recognized and classified. Together with the
abnormal anatomy and physiology identified by
the MRI, MRS gives a more complete picture of
disordered metabolism encountered in clinical
practice (Danielsen & Ross 1999, Rand et al. 1999,
Burtscher & Holtas 2001).  Proton MRS is also a
useful modality to detect biochemical abnormalities
at the molecular level in chronic alcoholics
(Jagannathan et al. 1996) and in congenital
hypothyroidism (Jagannathan et al. 1998) even
before structural damages are apparent in MRI.
In this section, a
 
few examples from the study
carried out in our laboratory are presented to show
the potential of in vivo MRS in actual clinical setting.
The transaxial MR image of a patient suffering from
brain tumor (cranio pharyngioma) in the floor of
the third ventricle is shown in figure 9A. Proton in
vivo MRS from an 8cc (20 ∗20 ∗ 20 mm3) volume
(voxel) from the normal posterior temporal region
of the brain shows (figure 9B) three major peaks
labeled as NAA, Cr and Cho.  NAA is an amino
acid and is generally considered to be a neuronal
marker. It is distributed throughout the cerebral
cortex with a concentration in the range of 7-15 mM.
Any change (mainly decrease) of NAA in relation to
a healthy brain tissue indicates altered metabolism
such as neuronal loss or neuronal death in variety of
brain tumors (table 3).  The total Cr (with PCr)
metabolite appears as a single peak at 3.00 ppm, and
is a reliable marker of intact brain ‘energy
metabolism’. Its normal concentration in human
brain is 4.0-5.5 mM. The TCho peak [arising from
phosphocholine (PC), glycerophosphocholine
(GPC) and free choline] is altered in many disease
processes (table 3) and its concentration in the
normal brain is approximately 1-2 mM. Myo-
inositol (mI), a sugar, appears around 3.54 ppm. It is
located in astrocytes where it is recognized as the
most important osmolyte, or cell volume regulator.
Glutamate and glutamine appear together as a
broad complex pattern near 2.3 ppm and is normally
denoted as “Glx”. Glutamine, like mI, is an
astrocyte marker, while glutamate functions as an
excitatory neurotransmitter, but obviously has a
number of other functions. Lactate is not
observed in normal brain and hence its
appearance is indicative of altered metabolism;
mainly failed oxidative metabolism in the brain
(table 3). A proton spectrum of the same patient
Table 3 Concentration of some brain biochemicals (metabolites) in normal and diseased states
Biochemical Increased (↑) Decreased (↓)
N-Acetyl-aspartate (NAA) 
(normal 7-15mM) 
Axonal recovery e.g. MS; infant 
development; hyperosmolar states; 
Canavan’s; post head injury. 
Hypoxia; anoxia; ischemia;   
Alzheimer’s and other dementia; 
developmental delay; epilepsy; MS; 
neoplasm; stroke; lymphoma; tumor; 
encephalitis; diabetes mellitus; 
Alexander’s; AIDS/HIV. 
Creatine (Cr) 
(normal 4-5 mM) 
Trauma (Hyperosmolar response); 
increase with age. 
Hypoxia; stroke; tumor; infant; trauma
lymphoma; hyponatremia; 
toxoplasmosis; PML 
Choline (Cho) 
(normal 1-2 mM) 
Trauma; diabetes; neonates; post liver 
transplant; tumor; chronic hypoxia; 
stroke; post liver transplant; 
hypersomolar. 
Asymptomatic liver disease; HE; 
toxoplasmosis; nonspecific dementia; 
hyponatremia 
Lactate (Lac) 
(normally less then 1 mM) 
Hypoxia; anoxia; ICH; near-drowning; 
stroke; Canavan’s; Alexander’s; 
hydrocephalus; lymphoma; 
toxoplasmosis. 
Lipids (Lip) Lymphoma; cryptococcoma; active 
growing tumor; PML; toxoplasmosis; MS; 
inflammatory  diseases. 
myo -inositol (mI)  
(normally 5 mm) 
Alzheimer’s  
Diabetes mellitus Hyperosmolar states; 
Neonate PML 
Chronic HE; stroke 
Tumor; lymphoma; 
Hypoxic encephalopathy 
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from a 8cc voxel from tumor shows (figure 9C)
the absence/reduction of the neuronal marker
(NAA) and the energy metabolic marker (Cr),
while the choline level is seen to be elevated,
indicating the presence of a tumor.
Seizures and epilepsies make up a
heterogeneous collection of episodes of disturbed
cerebral function. In a large number of patients with
seizures, MRI demonstrates atrophy and/or high-
signal intensity in the affected area. However, a
significant number of these patients has normal
MRI studies. The use of MRS is suggested in such
cases along with DWI investigations. Many reports
of single and multi-voxel proton MRS have been
reported. Common to all MRS studies is the
decrease in NAA in the affected area compared to
normal controls that represent neuronal dysfunction
and neuronal loss (Achten et al. 1997, Thompson
et al. 1998, Jackson & Connelly 1999, Rudkin &
Arnold 1999). MRS localizes unilateral seizure foci in
concordance with the EEG. In addition, it also
demonstrates the presence of high proportion of
bilateral abnormalities (Connelly et  al. 1994), which
can be difficult to observe by other techniques.
Observation of elevated lactate has been reported
in a limited number of studies (Matthews et al.
1990, Ng et al. 1994). The local increase in lactate can
persist for several hours and may be used as a more
direct marker of seizure activity (Danielsen & Ross
1999, Rudkin & Arnold 1999).  Studies have also
demonstrated elevated γ-amino butyric acid
(GABA) levels after treatment with vigabration, an
anticonvulsant that acts as an irreversible GABA
transaminase  inhibitor (Rotham et al. 1993, Petroff
et al. 1996).
Proton MRS methods have also been extensively
used to study acute and chronic functional
impairment in multiple sclerosis (MS) which results
from multiple mechanisms, including demyelination,
conduction block, and axonal injury. The main
finding in MS lesions is decreased NAA. However,
early increase in Cho and lactate, as well as early
transient decrease in Cr can be observed (Arnold
1999, Rudkin & Arnold 1999). Studies using short
echo times have shown  increased mI and lipid
signals (Davie et al. 1994). Recently, sequential proton
MRS studies of brain metabolite changes were
monitored during a complete pathological cycle of
demyelination and remyelination in experimental
demyelinating lesion model of MS (Degaonkar 2002).
Infectious CNS diseases are often the cause of
seizures
 
in the tropical countries like India, and these
are often caused by cysticercosis or tuberculosis. In
the absence of appropriate therapy, the disease can
be fatal, and noninvasive differential diagnosis
would be of great relevance. In fact, proton MR
spectroscopy has been found to be useful in patients
where radiological investigations are not specific
(Jayasundar et al. 1995, Jayasundar et al. 1999, Gupta
et al. 2001, Shukla et al. 2001, Venkatesh et al. 2001).
Local temperature in tumors, in addition to
influencing a number of normal biological functions
such as the protein activity, enzyme mediated
reactions, hemogloblin’s affinity for oxygen, etc. are
also known to play an important role in diseases
(Vanda et al. 1990). MRS is an ideal technique to
determine the local temperature of tumors
noninvasively. For example, even small variations in
brain temperature can affect the extent of injury in
brain ischemia (Jayasundar & Singh 2001). Therefore,
knowledge of local temperature  could provide
additional information on the pathophysiology of
the disease processes to the clinicians. Recently, few
papers have described the role of proton MRS to
measure tissue pH (Rothman et al. 1997, Pant et al.
1988, Van Sluis et al. 1999).
In our laboratory, the role of in vivo MRS in the
study of breast cancer was evaluated in 100 patients.
The MR image from one patient suffering form
infiltrating ducatal carcinoma (IDC) of the breast is
shown in figure 12A, while figure 12B is the proton
MRS from the normal region of the breast and
figure 12C is from the tumor.  Significant spectral
differences between the normal and tumor portions
of the breast is clearly visible. The presence of
choline from the tumor can be used as a metabolite
marker of malignancy and its level reduces/
disappears in patients treated with neoadjuvant
chemotherapy (NACT). Our study revealed that in
vivo proton MRS has 78% sensitivity and 86%
specificity in detecting choline in malignant breast
tumors. In comparison, the sensitivity and speci-
ficity of dynamic contrast MRI was 30-95% and
60 - 80%, respectively (Haywang-Kobrunner et al.
1997). Observation of choline before treatment and
its disappearance (or reduction) after treatment
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serve as
 
a useful indicator of response to treatment
(Jagannathan et al. 1998, 1999, 2001). Accurate
assessment of tumor response to treatment by MRS
helps in selecting patients for breast conservation.
Such studies have shown that in vivo MRS is a
beneficial, noninvasive technique to assess the
response of tumors to different drug treatments. In
general, monitoring the levels of various tumors
metabolites both prior to surgery/therapy and
after surgery/therapy helps the patient’s
therapeu-tic management (Tomi et al. 1997,
Jagannathan et al. 1998, 1999,  2001). It is also a
useful modality to monitor efficacy of different
drugs as well as testing of new drugs.
Spectroscopic Imaging (SI) or chemical shift
Imaging (CSI) is a technique that combines features
of both imaging and spectroscopy (Brown et al.
1982, Maudsley et al. 1983). It is a method for
collecting spectroscopic data from multiple adjacent
voxels covering a large VOI in a single measurement.
Spatial localization is done by phase encoding in one
(1D CSI), two (2D CSI), or three dimensions (3D
CSI). The sequences used for SI are similar to a MR
imaging sequence, but with no readout gradient
applied during data collection. The presentation of
the localized spectral data can be examined in
different ways: as single spectra related to
individual voxels, as spectral maps, or as metabolite
images. In fact, both the spectral maps and
metabolite images may be over laid on conventional
MR images. CSI is an efficient means for comparing
spectra from voxels containing different tissue
types. For example, in the case of focal diseases,
spectra from a lesion are compared to spectra from
normal brain tissues, and heterogeneous metabolic
distributions within the lesion may also be
investigated. A number of applications of SI
technique in the study of several brain pathologies
and breast cancers have been reported (Mukherji
1998, Danielsen & Ross 1999, Doyle et al. 1999,
Bernasconi et al. 2002).
1Fluorine (19F) MR Spectroscopy
Fluorine, which is 100% naturally abundant, has a
sensitivity of 83% to that of 1H and has relatively a
short T1. It is almost entirely absent in the human
body and hence a perfect tracer for NMR studies.
The only fluorine signal that will be detected comes
from the fluorine that is deliberately introduced
before the measurement. Many drugs, including
numerous psychoactive agents have fluorine as a
part of their molecular structure and hence can be
detectable by in vivo MRS. In addition, in vivo 19F
MRS can also be used to study the metabolism and
pharmacokinetics of these fluorinated drugs in
human liver in different combination regimens.
5-fluorouracil (5-FU) and other fluoropyri-
midines are anti-neoplastic agents that are widely
used either singly or concomitantly in the treatment
of human cancers, especially of the gastrointestinal
tract, breast and ovary.  The metabolism of these
drugs has been extensively studied. Figure 13
shows the pathway of 5-FU metabolism
(Heidelberger et al. 1983). The catabolic (detoxi-
fication) pathway of 5-FU involves hydrogenation
and opening of the pyrimidine ring, resulting in α-
fluoro-β-ureidopropionic acid and final products,
α-fluoro-β-alanine (FBAL), fluoride ion (F-), carbon
Figure 12 (A) T 1 – weighted sagittal MR image showing
the tumor of a patient suffering from infiltrating ductal
carcinoma (IDC) of the breast (slice thickness = 5 mm; TR
= 600 ms; TE = 15 ms); (B) Volume localized proton MR
spectrum from an 8 ml voxel positioned in the normal
position of the breast of the same patient (TR = 3000 ms;
TE = 135 ms; NS = 32); (C) Volume localized proton MR
spectrum from an 8 ml voxel from the tumor position of
the same patient (TR = 3000 ms; TE = 135 ms; NS = 64).
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dioxide, and ammonia. The liver remains the major
site for catabolism of 5-FU, since the activity of the
enzyme dihydrouracil dehydrogenase is the
highest in the liver.
To increase the response rate of 5-FU, other
agents are co-administered to modulate the efficacy
of 5-FU. Methotrexate (4-amino, 4-deoxy, N-10-
methyl pteroylglumaic acid) is one such modulator
that binds tightly but reversibly to its target enzyme
dihydrofolate reductase, leading to a cessation of
de novo purine synthesis. Other modulators that
are commonly used are leucovorin and levamisole.
The efficacy of these treatment regimens can be
assessed by in vivo 19F MRS. Numerous studies of
5-FU metabolism in animal models (Stevens et al.
1984, Sijens et al. 1999) and in humans (Wolf et al.
1987, Wolf et al. 1990, and Mohanakrishnan et al.
1999) are reported. The modulation by an effector
drug is actually monitored by measuring changes in
5-FU half-life or the time constant (t1/2) for the
formation of its catabolite, FBAL using in vivo 19F
NMR examination in the liver.
Figure 14 shows our data on the sequential 19F
NMR spectra carried out on a patient with breast
cancer (Mohanakrishnan et al. 1999). The initial
spectrum recorded in the first 3.5 minutes at the
onset of drug administration has only a single peak
at about 0 ppm due to 5-FU. In the second spectrum
recorded after 7 minutes, the signal intensity of this
peak increases and, another signal appears at about
–19 ppm that is assigned to FBAL on the basis of its
relative chemical shift. The 5-FU signal intensity
decreases and FBAL intensity increases with time in
subsequent spectra recorded at various timings as
shown. At about 21 minutes, no 5-FU signal is
visible. The apparent time constant (t1/2) for the
disappearance of 5-FU resonance and the appearance
of FBAL in liver are 15 ± 1.6 min and 25 ± 2.2 min,
respectively. The t1/2 for 5-FU in liver among 9
patients studied by us under different combination
regimens of modulators varied between 5 and 17
min and this agrees with the t1/2 for 5-FU in blood.
The t1/2 values of 5-FU trapped in tumors ranged
between 20 and 78 minutes. In spite of the increase
in t1/2  values for intratumoral 5-FU, fluorinated
nucleoside/nucleotide signals were not detected. It
Figure 13  Pathways of 5-FU metabolism. The different
products of the metabolic pathways are:
 
5 – FU (5-fluorouracil);
FUR (5-fluorouridine); FUdR (5-fluoro-2’ –deoxyuridine);
FUMP, FUDP, FUTP (5-fluorouridine –51’ – mono-, di-,
triphosphate); FdUMP, FdUDP, FdUTP, (5-fluoro-2’ –
deoxyuridine –5’ – mono-, di-, triphosphate);  5FUH2 (5, 6-
dihdro- 5-fluorouracil); FUPA (± – fluoro – ²-ureidopropionic
acid); FBAL (± – fluoro – ²-alanine); F- (fluoride ion).
Figure 14  Stacked in vivo 19F MR spectra at 60.1 MHz as
a function of time from the liver of a breast cancer patient
following the bolus infusion of 5–FU two hours after
methotrexate administration.
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may be possible that 5-fluoro-2’-deoxyuridine 5’
monophosphate (FdUMP) formed is rapidly
incorporated into DNA/RNA and the fluorine
signals from these macromolecules are too broad to
detect. Based on the results obtained from a
number of patients who were receiving 5-FU and
additional chemotherapeutic agents such as
methotrexate, leucovorin or levamisole, it is
concluded that the modulators of 5-FU do not
significantly lengthen the time constant for the
disappearance of 5-FU from the liver
(Mohanakrishnan et al. 1999). 19F MRS has also been
used to study the concentration level in the brain of
antipsychotic drugs such as trifluoperazine and
fluphenazine and the antidepressant fluoxetine
(Durst et al. 1990, Renshaw et al. 1992, Komoroski
et al. 1995).
Lithium  (7Li) MR Spectroscopy
The isotope 7Li has a spin 3/2, receptivity about
27% of 1H, and is a relatively attractive nucleus for
NMR studies. It typically gives a single narrow
line in most biological systems arising from the Li
cation, in both the intracellular and extracellular
environments. Lithium salts are used with
considerable success in alleviating or preventing
both depressive and manic recurrences of manic-
depressive illness. There is a considerable interest
on its clinical effects, pharmacokinetics and
mechanism of action. However, its mechanism of
action remains unknown. Patient monitoring relies
on measurement of the Li level in serum and the
range 0.5-1.2 mmol/L considered to be the
optimum level and those greater than 2.0 mmol/L,
are toxic. Of course, serum levels may not reflect
brain concentrations, which might be expected to
relate more closely to clinical response. Patient
monitoring and elucidation of Li biochemistry in
vivo are difficult due to lack of suitable methods to
follow the distribution, concentration and physical
state, for example, degree of ion binding, etc., of Li
in various organs. There is no known method for
following Li concentration in vivo in humans
available except NMR spectroscopy although a
neutron activation method has been proposed.
Renshaw and co-workers have extensively
studied the application of 7Li NMR in vivo
spectroscopy (Gonzalez et al. 1993).
Figure 15 shows the results obtained by
Komoroski et al. (1990) of a patient suffering from
manic-depressive illness with an episode of
hypomania. The patient was under Li therapy (900
mg/day of Li2C O3 in three doses). The serum level
of Li rises to about 0.75 mmol/L in 8 days, and then
drops to 0.6 mmol/L. The drop occurred during a
brief release of the patient from the hospital
indicating the suspicion of noncompliance with
therapy during this period. The Li level in muscle
rises steadily through the seventh day, dropping
precipitously thereafter. The brain Li level rose more
rapidly than that for muscle initially, then more
slowly thereafter. Thus, it appears that the Li level
in muscle more closely follows the serum level.
Several other workers have also noticed that the Li
level in brain is about half those in serum
(Komoroski et al. 1990, Kato et al. 1992). Gonzalez
et al. (Komoroski et al. 1993) have measured the Li
level in the brain by computerized morphometric
analysis and compared it that obtained from muscle,
cerebrospinal fluid, and blood obtained using MRS.
The important issue is the compartmentation of the
Li  ion  in vivo and  ignoring the different cell types,
the ratio of intracellular-to-extracellular Li
concentration is not known in brain. Li presumably
works intracellularly in the brain and about 80% of
the volume of the brain is intracellular; the
intracellular concentration may be substantially
lower than extra cellular concentration, as is the case
for Na. Thus, the in vivo Li signal may primarily
represent non active Li, however, it is very
difficult to find out the ratio of the intracellular-
to-extracellular Li concentrations (Komoroski
1993). The compartmentation issue can probably
be solved by in vivo perfusion studies of cultured
cells (Komoroski 1993).
Figure 15 Pharmacokinetics of lithium by 7Li NMR in
serum, brain and calf muscle of a patient suffering from
bipolar illness.
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Conclusions
MR due to its multiplanar imaging capability, high
spatial resolution, excellent soft tissue contrast,
and the absence of ionizing radiation is well
established as a tool in clinical, experimental and
biological  research. It covers a broad range of
applications from fast noninvasive anatomical
measurements, to studies on tissue physiology
and metabolism.  Since it is noninvasive, studying
chronic diseases both in humans and animals has
several advantages for repeated monitoring of
disease progression and therapy response. The
method is also highly desirable when studying
transgenic and knockout animals. A major use of
MR in experimental animal research is the
possibility of directly linking pre-clinical to
clinical findings. MR can also be used for
pharmacodynamic studies in humans to assess
whether new compounds are exerting the same
pharmacological effects in patients as in animals.
Such studies will serve and guide the dose
selection for the extensive and expensive clinical
efficacy trials. As MR technology matures, the
technological limits on the achievable scanning
speed and pixel resolution are rapidly
approaching the limits imposed by the laws of
physics.
Due to the high natural abundance of hydrogen,
and its ubiquity in all in vivo metabolites, it has
been the focus of many clinical MRS studies. The
potentially powerful feature of in vivo MRS is the
ability to measure endogenous metabolites
noninvasively as well as changes in tissue
metabolism for example, by 1H or 31P MRS
monitoring of endogenous metabolites (such as
energy metabolism, acidosis, etc.). The technique
can also be used for measuring the distribution, and
pharmacokinetics of drug in vivo, in both humans
and animal systems. MRS is currently employed for
clinical investigation in many sites around the
world, including India. The sensitivity and
specificity of in vivo MRS for several disease
patterns, particularly for small lesions, need to be
improved before MRS can be incorporated into
clinical practice.  Presently, MRS is acting as a
complementary tool to histology, mammography
and other accepted techniques. However, once MRS
becomes established for clinical use unambiguously
in one disease, it can be expected that the available
technology will be more rapidly be applied to other
diseases. In fact, MRS already has great clinical
impact in the localization of foci and brain damage in
epilepsy and represents a valuable complement to
conventional imaging techniques such as CT and
MRI.  The ability to perform MRI and MRS
noninvasively in the same setting with the same
equipment with out the injection of radioactive
isotopes or blood sampling provides a considerable
advantage in patient care.
Future of MR
The future is incredibly optimistic for MR in clinical
and experimental research. In less than twenty five
years of its induction as a diagnostic modality in
clinical radiology, amazing changes have taken place
in generating fast high-resolution images with
thinner slices, noninvasive brain functionality, etc.
MRI has also been developed as a powerful tool to
guide interventional procedures in clinical medicine.
Designs of new open magnet systems allow
improved patient access for MR-guided
interventional procedures with the use of MR-
compatible needles and catheters. Applications of this
interventional MRI include aspiration cytology,
chemoablation, cryoblation, etc.  The new genera-
tion high field strengths MR operating at 3 and 4 Tesla
would enable greater detection sensitivity and
increased chemical shift dispersion especially for
MRS. MR spectroscopy still provides more
challenges and can be expected to expand to other
clinical areas such as therapy monitoring. MRS,
whether it can answer several diagnostic challenges
above and beyond MRI, SPECT, PET, and CT will
depend on further clinical studies and future
technical developments.  The future of MR is very
bright. The rapid development of new and exciting
research will soon provide a virtually limitless ability
to accurately diagnose and provide better treatment
for patients. This would understandably be a
remarkable achievement in medicine made possible
through ingenious use of physics.
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